CrazyZ
SENIOR MEMBER
- Joined
- Mar 3, 2019
- Messages
- 4,617
- Reaction score
- 2
- Country
- Location
Gilead looking for drug-maker partners for its coronavirus experimental drug
Published: May 5, 2020 at 5:54 p.m. ET
By
Claudia Assis
3
Gilead Sciences Inc. GILD, -1.38% said late Tuesday it was "in discussions" with unnamed chemical and pharmaceutical companies to make remdesivir, its anti-viral drug that has emerged as a potential treatment for COVID-19, for Europe, Asia and the developing world through at least 2022 under licenses. Gilead said it is also negotiating long-term licenses with "several" generic drug makers in India and Pakistan to produce remdesivir for developing countries, also without identifying the companies. "Gilead will provide appropriate technology transfers to facilitate this production," the Foster City, Calif., company said in a statement. Gilead said it was also collaborating with the Medicines Patent Pool, a United Nations-backed organization in Switzerland, to license remdesivir for developing countries. To ease the distribution of the drug, which on Friday got an emergency use authorization from the Food and Drug Administration, the California company said it was in "advanced discussions" with Unicef about tapping the United Nation agency's experience in providing medicine in poorer countries amid crises. Shares of Gilead were 0.5% lower in the extended session after ending the regular trading day down 1.4%.
https://www.marketwatch.com/story/g...-its-coronavirus-experimental-drug-2020-05-05
Published: May 5, 2020 at 5:54 p.m. ET
By
Claudia Assis
3
Gilead Sciences Inc. GILD, -1.38% said late Tuesday it was "in discussions" with unnamed chemical and pharmaceutical companies to make remdesivir, its anti-viral drug that has emerged as a potential treatment for COVID-19, for Europe, Asia and the developing world through at least 2022 under licenses. Gilead said it is also negotiating long-term licenses with "several" generic drug makers in India and Pakistan to produce remdesivir for developing countries, also without identifying the companies. "Gilead will provide appropriate technology transfers to facilitate this production," the Foster City, Calif., company said in a statement. Gilead said it was also collaborating with the Medicines Patent Pool, a United Nations-backed organization in Switzerland, to license remdesivir for developing countries. To ease the distribution of the drug, which on Friday got an emergency use authorization from the Food and Drug Administration, the California company said it was in "advanced discussions" with Unicef about tapping the United Nation agency's experience in providing medicine in poorer countries amid crises. Shares of Gilead were 0.5% lower in the extended session after ending the regular trading day down 1.4%.
https://www.marketwatch.com/story/g...-its-coronavirus-experimental-drug-2020-05-05
